Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$158.56 USD

158.56
5,625,135

-2.08 (-1.29%)

Updated Jul 29, 2024 04:00 PM ET

After-Market: $158.55 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 26% (185 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Kinjel Shah headshot

How Should You Play J&J (JNJ) Stock After Q2 Earnings Beat?

Though J&J (JNJ) beat estimates for both earnings and sales in the second quarter, a new investor should avoid buying the stock right now due to its legal troubles.

AbbVie (ABBV) Beats on Q2 Earnings & Sales, Ups '24 EPS View

AbbVie's (ABBV) second-quarter earnings and sales beat estimates. Management hikes the EPS guidance on encouraging product sales for immunology drugs.

Sundeep Ganoria  headshot

GSK Stock Before Q2 Earnings: To Buy or Not to Buy?

We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Trelegy Ellipta and Shingrix to drive second-quarter sales performance.

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Sanghamitra Saha headshot

Time for Healthcare ETFs?

Compelling valuation, innovation in specific growth areas and an aging population as well as increasing healthcare spending are the tailwinds of the medical sector.

GSK Blenrep Combos for Multiple Myeloma Accepted for EU Review

GSK announces the acceptance of its regulatory filing, seeking the approval of Blenrep combinations for the treatment of relapsed or refractory multiple myeloma, for review in the EU.

Sundeep Ganoria  headshot

AbbVie (ABBV) Stock Before Q2 Earnings: To Buy or Not to Buy?

Investor focus will likely be on sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports second-quarter results.

Should You Invest in the Vanguard Health Care ETF (VHT)?

Sector ETF report for VHT

Kinjel Shah headshot

Pharma Stock Roundup: JNJ, NVS Q2 Earnings, RHHBY's Positive Obesity Pill Data

J&J (JNJ) and Novartis (NVS) beat estimates for earnings and sales. Roche's (RHHBY) oral weight loss GLP-1 therapy achieves positive results in an early-stage study.

Company News for Jul 18, 2024

Companies in The News Are: JNJ,SYF,CFG,FHN

Kinjel Shah headshot

J&J (JNJ) Q2 Earnings & Sales Top, EPS View Cut on M&A Costs

J&J (JNJ) beats estimates for second-quarter earnings and sales. It lowers earnings expectations for 2024 due to costs related to recent acquisitions.

ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ

ORIC Pharmaceuticals (ORIC) teams up with Bayer and Johnson & Johnson for a phase I study on ORIC-944 in patients with metastatic prostate cancer. Its shares rise on the news.

Housing Starts Increased More Than Expected

Housing Starts Increased More Than Expected

Mark Vickery headshot

Pre-Markets Book Profits; Housing Starts, J&J Q2 Up

Pre-market futures are down at this hour, but not apparently as a result of any new reports ahead of the bell.

Johnson & Johnson (JNJ) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Johnson & Johnson (JNJ) Beats Q2 Earnings and Revenue Estimates

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 4.06% and 0.43%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Stock Market News for Jul 16, 2024

U.S stocks closed higher on Monday, building on Friday???s rally, as investors increased their bets on the chances of Donald Trump winning the U.S. presidential election in November following a failed assassination attempt on the Republican nominee over the weekend.

Mark Vickery headshot

Dow Closes at New High as Q2 Earnings Season Heats Up

Earnings season only picks up steam in the weeks to come.

Q2 Earnings Parade Continues

Q2 Earnings Parade Continues

Kinjel Shah headshot

J&J (JNJ) Stock Before Q2 Earnings: To Buy or Not to Buy?

J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.

Mark Vickery headshot

Pre-Markets Up as 1st Full Week of Q2 Earnings Begins

Goldman Sachs (GS) and BlackRock (BLK) both beat on Q2 earnings this morning, and we're just getting started.

Legend Biotech (LEGN) Up 12% on Reports of Takeover Bid

A third-party article suggests that Legend Biotech (LEGN) hired investment banking firm Centerview Partners to help its board review the takeover offer.

Derek Lewis headshot

3 Key Earnings Reports to Watch Next Week

With the 2024 Q2 earnings season kicking into a much higher gear next week, there are several reports investors should keep on their radars, including these three.

Unlocking Q2 Potential of Johnson & Johnson (JNJ): Exploring Wall Street Estimates for Key Metrics

Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Johnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should Know

In the most recent trading session, Johnson & Johnson (JNJ) closed at $149.43, indicating a +1.62% shift from the previous trading day.